Search
PPI-1019
go.drugbank.com/drugs/DB05832InvestigationalApan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
BF-1
go.drugbank.com/drugs/DB06029ExperimentalBF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.
CX-717
go.drugbank.com/drugs/DB05047IllicitInvestigationalCX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
CZEN 002
go.drugbank.com/drugs/DB05479ExperimentalThis organism can invade tissues and produce fatal infections in individuals with compromised immune systems such as those suffering from HIV/AIDS or undergoing organ or bone transplants.
Danegaptide
go.drugbank.com/drugs/DB11821InvestigationalDanegaptide has been investigated for the treatment of Focus of Study is STEMI.
OSI-930
go.drugbank.com/drugs/DB05913InvestigationalOSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angio...
Voglibose
go.drugbank.com/drugs/DB04878InvestigationalVoglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.
Omburtamab
go.drugbank.com/drugs/DB15635InvestigationalCD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for us...
Teglarinad chloride
go.drugbank.com/drugs/DB05217InvestigationalGMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond....
RI 624
go.drugbank.com/drugs/DB05892ExperimentalRI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.